Related Experiment Videos
Cyclosporin for severe ulcerative colitis attacks.
Ahmet Danalioglu1, Sabahattin Kaymakoglu, Zeynel Mungan
1Istanbul University, Istanbul School of Medicine, Gastroenterohepatology Department, Turkey.
Hepato-Gastroenterology
|July 13, 2004
Summary
Cyclosporin-A offers initial remission for severe ulcerative colitis patients refractory to steroids. Long-term data shows a significant portion maintain remission and their colon after treatment.
Area of Science:
- Gastroenterology
- Immunosuppressive Therapy
- Inflammatory Bowel Disease
Background:
- Ulcerative colitis (UC) management often involves steroids.
- Steroid-refractory UC presents a therapeutic challenge.
- Cyclosporin-A is an alternative therapy for severe, steroid-refractory UC.
Purpose of the Study:
- To assess the long-term outcomes of Cyclosporin-A therapy in severe, steroid-refractory ulcerative colitis.
- To evaluate remission rates and colectomy incidence following Cyclosporin-A treatment.
Main Methods:
- Retrospective analysis of 13 patients with severe, steroid-refractory UC treated with Cyclosporin-A.
- Cyclosporin-A administered orally or intravenously, with subsequent oral transition.
- Concomitant use of 5-ASA, azathioprine, and steroid tapering.
Main Results:
- Initial clinical response observed in 10 out of 13 patients (77%) within a mean of 9 days.
- Three patients (23%) did not respond and underwent colectomy.
- Among responders, 50% (5 patients) relapsed during or after therapy; 4 underwent colectomy.
- Five patients (38% overall, 50% of initial responders) maintained remission for an average of 17 months, retaining their colon.
Conclusions:
- Cyclosporin-A induces initial remission in approximately 80% of severe, steroid-refractory UC patients.
- Approximately 40% of patients may retain their colon for up to one year with Cyclosporin-A therapy.
- Long-term efficacy and relapse rates necessitate careful patient selection and monitoring.